

1.2 x

Buy	
EUR 9.50	
Price	EUR 6.38
Upside	48.9 %

Value Indicators:	EUR
DCF:	9.60
FCF-Value Potential 21e:	5.00
Market Snapshot:	EUR m
Market cap:	58.1
No. of shares (m):	9.1
EV:	70.5
Freefloat MC:	36.4
Ø Trad. Vol. (30d):	22.33 th

Share data:	
Bloomberg:	SYT GR
Reuters:	SYTG
ISIN:	DE0005178008
Shareholders:	
Freefloat	62.6 %
Trier Asset Mgmt	22.4 %

Alois Widmann

	Description:	
:	Soft- and hardware for dat exchange for e.g. industria	
;	and automotive electronics	
	Risk Profile (WRe):	2019e
6	Beta:	1.3
6	Price / Book:	0.9 x
6	Equity Ratio:	60 %
	Net Fin. Debt / EBITDA:	1.0 x

Net Debt / EBITDA:

Strong order backlog indicates a continuation of Q2 operative momentum

Softing had a solid second quarter.

In the Industrial segment, Softing continues to benefit from demand for its solutions for process automation and factory automation. Demand in factory automation reflects the ongoing connectivity and digitalization in production facilities which creates demand for Softing's IoT Gateways, OPC Servers and middleware. Softing's operative development in the second half of the year should benefit from the delivery of products related to large orders already on hand.

Revenue development in the IT Networks segment reflects the discontinuation of the lower-margin reselling business. As these revenues are replaced by proprietary products, segment profits remained unchanged and should grow in future.

Softing - Q2 2019								
in EUR m	Q2/19	Q2/19e	ΔWRe	Q2/18	уоу	6 M / 19	6M / 18	yoy
Sales	22.2	22.4	-0.8%	21.4	3.8%	418	39.9	4.8%
EBIT	2.3	1.3	78.4%	0.7	234.1%	18	1.1	70.1%
margin	10.4%	5.8%		3.2%		4.4%	2.7%	
EPS in EUR	0.15	0.16	-6.3%	0.10	50.0%	0.12	0.11	9.1%
Industrial	14.5	14.0	3.5%	13.3	9.0%	27.9	24.9	119%
Automotive	5.0	5.0	0.4%	4.5	11.9%	9.0	8.7	3.6%
IT Networks	2.7	3.3	-17.3%	3.6	-25.1%	4.9	6.3	-217%
Order entries	24.7			23.3	6.1%	51.1	44.4	15.1%
Book-to-bill	11			11	2.2%	12	1.1	9.9%

15.0 %

Sources: Softing (historical data), Warburg Research (estimates)

Group profitability benefitted from a more favourable product mix. Own work capitalised was also higher than in previous quarters owing to Softing's R&D efforts and new product developments.

The Automotive segment grew by 12% in Q2. In June, Softing signed a contract for its last-generation diagnostic tool set (DTS) with a leading German automotive manufacturer. With this contract, Softing will generate a seven-digit EUR annual revenue volume. This reference should support further customer wins, e.g. on the Asian market.

In May, Globalmatix signed a contract with a subsidiary of a large German automobile manufacturer to supply data transmission services and hardware for the control of mixed-brand, commercially used vehicle fleets. The marketing of the service products by the major customer is scheduled to start in the third quarter of 2019. With a gradual ramp-up and the connection of more than 200,000 vehicles during the initial contract period of five years, revenues should reach an annual level of approx. EUR 10-15m. This order has already attracted the attention of further large potential customers. Additional growth o pportunities are offered by the market size (12m fleet cars in Europe) and a myriad of use

Sequentially, the order book increased by about EUR 4m indicating strong operative momentum despite growing economic uncertainty. The order backlog increases visibility for the remainder of the year. The Buy rating is confirmed.








FY End: 31.12. in EUR m	CAGR (18-21e)	2015	2016	2017	2018	2019e	2020e	2021e
Sales	7.4 %	82.3	80.4	78.7	83.9	90.0	96.0	104.0
Change Sales yoy		10.4 %	-2.3 %	-2.1 %	6.6 %	7.3 %	6.7 %	8.3 %
Gross profit margin		64.7 %	66.6 %	64.9 %	61.8 %	60.8 %	62.2 %	61.2 %
EBITDA	16.3 %	10.8	12.3	6.8	9.0	10.3	12.2	14.2
Margin		13.1 %	15.2 %	8.7 %	10.7 %	11.4 %	12.7 %	13.6 %
EBIT	24.0 %	5.5	7.2	2.3	4.1	3.9	5.8	7.8
Margin		6.6 %	8.9 %	3.0 %	4.9 %	4.3 %	6.0 %	7.5 %
EBIT adj.	27.3 %	6.7	6.6	1.1	3.5	3.9	5.3	7.3
Net income	17.5 %	4.5	5.7	0.7	3.3	2.6	4.0	5.4
EPS	15.8 %	0.65	0.82	0.10	0.38	0.29	0.44	0.59
DPS	15.4 %	0.15	0.20	0.13	0.13	0.15	0.17	0.20
Dividend Yield		1.2 %	1.7 %	1.2 %	1.5 %	2.4 %	2.7 %	3.1 %
FCFPS		0.61	0.56	-0.27	0.19	0.24	0.18	0.29
FCF / Market cap		4.8 %	4.8 %	-2.4 %	2.3 %	3.8 %	2.8 %	4.5 %
EV / Sales		1.2 x	1.1 x	1.1 x	1.0 x	0.8 x	0.7 x	0.7 x
EV / EBITDA		9.4 x	7.3 x	12.7 x	8.9 x	6.9 x	5.9 x	5.1 x
EV / EBIT adj.		15.1 x	13.6 x	77.7 x	22.8 x	18.3 x	13.5 x	9.9 x
EV / EBIT		18.6 x	12.6 x	37.0 x	19.7 x	18.3 x	12.4 x	9.3 x
P/E		19.4 x	14.3 x	112.0 x	22.6 x	22.0 x	14.5 x	10.8 x
FCF Potential Yield		6.6 %	7.5 %	2.6 %	2.4 %	2.8 %	4.6 %	6.5 %
Net Debt		13.9	8.3	4.5	5.2	12.4	13.6	14.1
ROCE (NOPAT)		8.4 %	10.5 %	2.7 %	4.5 %	3.5 %	5.0 %	6.5 %
Guidance: 2	019: revenue	s > EUR 88n	n; EBIT > EL	JR 4m				






Company Background

- Softing has the necessary expertise on information exchange between various devices, sensors, plant and software solutions in automated processes. Its business activity comprises three segments.
- Industrial Automation: hardware and software solutions for the exchange of information in all kinds of production including assembly lines, chemical plants, oil and gas extraction or refineries.
- IT Networks: diagnostic devices which are used in industrial automation and for the diagnosis of copper and optical fibre networks in data centers and office installations
- Automotive Electronics: The solutions allow engineers and workshop mechanics to test automotive electronics in the development phase, production or repair and to recognise errors via data evaluation.
- The solutions in the automotive segment are not for application within the vehicles and therefore do not pose a product re-call risk for the company.

Competitive Quality

- European market leader in the networking of various production plant elements as well as in business-related software (so-called OPC products).
- World market leader in components for the exchange of information in gas and oil plants. Some >50% of all devices registered worldwide that are used in these plants include components from Softing.
- Softing's participation in international committees that set standards for the exchange of information. This contributes to a short time-to-market.
- The high complexity of Softing's business activity is the single most important barrier to market entry for potential competitors.



Source: Company



DCF model														
	Detailed	d forecas	t period				٦	ransition	al period					Term. Value
Figures in EUR m	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	
Sales	90.0	96.0	104.0	109.7	115.5	121.2	126.9	132.6	138.2	143.8	149.3	154.8	157.9	
Sales change	7.3 %	6.7 %	8.3 %	5.5 %	5.2 %	5.0 %	4.7 %	4.5 %	4.3 %	4.0 %	3.8 %	3.6 %	2.0 %	2.0 %
EBIT	3.9	5.8	7.8	8.2	8.7	9.1	9.5	9.9	10.4	10.8	11.2	11.6	11.8	
EBIT-margin	4.3 %	6.0 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	7.5 %	
Tax rate (EBT)	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	
NOPAT	2.7	4.1	5.4	5.8	6.1	6.4	6.7	7.0	7.3	7.6	7.8	8.1	8.3	
Depreciation	6.4	6.4	6.4	7.6	8.0	8.4	8.8	9.1	9.5	9.9	10.3	10.7	10.9	
in % of Sales	7.1 %	6.7 %	6.2 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	
Changes in provisions	0.4	0.0	0.0	-0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	
Change in Liquidity from														
- Working Capital	-0.4	1.2	1.6	1.3	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1	0.6	
- Capex	7.6	7.6	7.6	7.6	8.0	8.4	8.8	9.1	9.5	9.9	10.3	10.7	10.9	
Capex in % of Sales	8.4 %	7.9 %	7.3 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	6.9 %	
Other	1.5	1.5	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	0.7	0.2	1.2	4.3	5.0	5.3	5.6	5.9	6.3	6.6	6.9	7.2	7.7	8
PV of FCF	0.7	0.2	1.0	3.4	3.7	3.6	3.6	3.5	3.4	3.3	3.2	3.1	3.1	56
share of PVs		2.11 %						36.80) %					61.09 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2031e	36		
				Terminal Value	56		
Debt ratio	10.00 %	Financial Strength	1.30	Financial liabilities	13		
Cost of debt (after tax)	2.1 %	Liquidity (share)	1.30	Pension liabilities	2		
Market return	7.00 %	Cyclicality	1.30	Hybrid capital	0		
Risk free rate	1.50 %	Transparency	1.25	Minority interest	0		
		Others	1.30	Market val. of investments	0		
				Liquidity	10	No. of shares (m)	9.1
WACC	7.95 %	Beta	1.29	Equity Value	87	Value per share (EUR)	9.58

Sens	itivity Va	lue per Sh	are (EUR)													
	Terminal Growth								Delta EBIT-margin								
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.49	8.9 %	7.41	7.56	7.71	7.88	8.06	8.25	8.45	1.49	8.9 %	5.79	6.48	7.18	7.88	8.58	9.27	9.97
1.39	8.4 %	8.09	8.27	8.46	8.66	8.88	9.12	9.37	1.39	8.4 %	6.40	7.16	7.91	8.66	9.41	10.16	10.91
1.34	8.2 %	8.47	8.67	8.87	9.10	9.34	9.61	9.90	1.34	8.2 %	6.75	7.53	8.32	9.10	9.88	10.66	11.44
1.29	7.9 %	8.88	9.09	9.33	9.58	9.85	10.15	10.47	1.29	7.9 %	7.13	7.95	8.76	9.58	10.39	11.21	12.02
1.24	7.7 %	9.32	9.56	9.82	10.10	10.40	10.74	11.11	1.24	7.7 %	7.54	8.39	9.25	10.10	10.95	11.80	12.65
1.19	7.4 %	9.80	10.06	10.35	10.67	11.01	11.39	11.81	1.19	7.4 %	8.00	8.89	9.78	10.67	11.56	12.45	13.34
1.09	6.9 %	10.88	11.22	11.58	11.98	12.43	12.92	13.48	1.09	6.9 %	9.04	10.02	11.00	11.98	12.96	13.94	14.92

[•] The cyclical components of the business activity and the low liquidity of the share raise capital costs.



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2015	2016	2017	2018	2019e	2020e	2021e
Net Income before minorities	4.5	5.7	0.7	3.3	2.6	4.0	5.4
+ Depreciation + Amortisation	5.3	5.1	4.5	4.9	6.4	6.4	6.4
- Net Interest Income	-0.3	-0.2	-1.2	0.5	-0.1	-0.1	-0.1
- Maintenance Capex	3.3	4.2	4.2	5.8	5.7	5.7	5.7
+ Other	0.0	0.0	0.0	0.0	-1.5	-1.5	-1.5
= Free Cash Flow Potential	6.7	6.8	2.3	1.9	2.0	3.3	4.7
FCF Potential Yield (on market EV)	6.6 %	7.5 %	2.6 %	2.4 %	2.8 %	4.6 %	6.5 %
WACC	7.95 %	7.95 %	7.95 %	7.95 %	7.95 %	7.95 %	7.95 %
= Enterprise Value (EV)	101.6	90.0	86.7	80.5	70.5	71.7	72.2
= Fair Enterprise Value	84.3	85.5	28.4	24.5	24.6	41.7	59.1
- Net Debt (Cash)	3.1	3.1	3.1	3.1	9.9	11.1	11.6
- Pension Liabilities	2.1	2.1	2.1	2.1	2.5	2.5	2.5
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
- Market value of minorities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	79.0	80.3	23.2	19.3	12.3	28.1	45.1
Number of shares, average	6.9	7.0	7.3	8.8	9.1	9.1	9.1
= Fair value per share (EUR)	11.39	11.54	3.16	2.20	1.35	3.09	4.95
premium (-) / discount (+) in %					-78.9 %	-51.6 %	-22.4 %
Sensitivity Fair value per Share (EU	R)						
10.	95 % 6.14	6.24	1.69	1.38	0.60	1.83	3.17
9.	95 % 6.82	6.93	1.92	1.58	0.80	2.16	3.64
8.	95 % 7.65	7.77	2.20	1.82	1.04	2.57	4.22
WACC 7.	95 % 8.68	8.82	2.55	2.12	1.35	3.09	4.95
6.	95 % 10.01	10.17	3.00	2.51	1.74	3.75	5.89
5.	95 % 11.79	11.98	3.60	3.02	2.26	4.63	7.14
4.	95 % 14.29	14.51	4.44	3.75	2.99	5.87	8.89

[·] Capitalised own work is a significant element of the capex.

[•] FCF-Value-CAGR 2015-2021e: -9%

Softing



Valuation							
	2015	2016	2017	2018	2019e	2020e	2021e
Price / Book	2.1 x	1.7 x	1.6 x	1.1 x	0.9 x	0.8 x	0.8 x
Book value per share ex intangibles	0.00	0.55	1.37	0.92	0.64	0.56	0.60
EV / Sales	1.2 x	1.1 x	1.1 x	1.0 x	0.8 x	0.7 x	0.7 x
EV / EBITDA	9.4 x	7.3 x	12.7 x	8.9 x	6.9 x	5.9 x	5.1 x
EV / EBIT	18.6 x	12.6 x	37.0 x	19.7 x	18.3 x	12.4 x	9.3 x
EV / EBIT adj.*	15.1 x	13.6 x	77.7 x	22.8 x	18.3 x	13.5 x	9.9 x
P / FCF	20.8 x	20.9 x	n.a.	44.1 x	26.7 x	35.7 x	22.3 x
P/E	19.4 x	14.3 x	112.0 x	22.6 x	22.0 x	14.5 x	10.8 x
P / E adj.*	19.4 x	14.3 x	112.0 x	22.6 x	22.0 x	14.5 x	10.8 x
Dividend Yield	1.2 %	1.7 %	1.2 %	1.5 %	2.4 %	2.7 %	3.1 %
FCF Potential Yield (on market EV)	6.6 %	7.5 %	2.6 %	2.4 %	2.8 %	4.6 %	6.5 %
*Adjustments made for: -							


Company Specific Items											
	2015	2016	2017	2018	2019e	2020e	2021e				
order entries	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.				
book-to-bill	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.				
order book	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.				



Consolidated profit & loss							
In EUR m	2015	2016	2017	2018	2019e	2020e	2021
Sales	82.3	80.4	78.7	83.9	90.0	96.0	104.0
Change Sales yoy	10.4 %	-2.3 %	-2.1 %	6.6 %	7.3 %	6.7 %	8.3 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	2.8	4.5	4.6	4.4	4.0	4.5	4.5
Total Sales	85.1	84.9	83.3	88.3	94.0	100.5	108.5
Material expenses	31.9	31.4	32.2	36.5	39.2	40.8	44.8
Gross profit	53.2	53.6	51.1	51.8	54.8	59.7	63.7
Gross profit margin	64.7 %	66.6 %	64.9 %	61.8 %	60.8 %	62.2 %	61.2 %
Personnel expenses	33.6	35.1	33.0	33.4	36.0	36.5	38.0
Other operating income	2.8	5.3	0.9	1.4	1.5	1.5	1.5
Other operating expenses	11.7	11.5	12.1	10.8	10.0	12.5	13.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	10.8	12.3	6.8	9.0	10.3	12.2	14.2
Margin	13.1 %	15.2 %	8.7 %	10.7 %	11.4 %	12.7 %	13.6 %
Depreciation of fixed assets	0.8	0.8	0.8	0.7	1.9	1.9	1.9
EBITA	10.0	11.4	6.1	8.3	8.4	10.3	12.3
Amortisation of intangible assets	4.5	4.3	3.7	4.2	4.5	4.5	4.5
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	5.5	7.2	2.3	4.1	3.9	5.8	7.8
Margin	6.6 %	8.9 %	3.0 %	4.9 %	4.3 %	6.0 %	7.5 %
EBIT adj.	6.7	6.6	1.1	3.5	3.9	5.3	7.3
Interest income	0.1	0.1	0.0	0.1	0.1	0.1	0.1
Interest expenses	0.3	0.2	1.3	-0.5	0.2	0.2	0.2
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	5.2	7.0	1.1	4.6	3.8	5.7	7.7
Margin	6.3 %	8.7 %	1.4 %	5.5 %	4.2 %	5.9 %	7.4 %
Total taxes	0.7	1.3	0.4	1.3	1.1	1.7	2.3
Net income from continuing operations	4.5	5.7	0.7	3.3	2.6	4.0	5.4
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	4.5	5.7	0.7	3.3	2.6	4.0	5.4
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	4.5	5.7	0.7	3.3	2.6	4.0	5.4
Margin	5.4 %	7.1 %	0.9 %	4.0 %	2.9 %	4.2 %	5.2 %
Number of shares, average	6.9	7.0	7.3	8.8	9.1	9.1	9.1
EPS	0.65	0.82	0.10	0.38	0.29	0.44	0.59
EPS adj.	0.65	0.82	0.10	0.38	0.29	0.44	0.59
*Adjustments made for:							

Guidance: 2019: revenues > EUR 88m; EBIT > EUR 4m


Financial Ratios								
	2015	2016	2017	2018	2019e	2020e	2021e	
Total Operating Costs / Sales	90.3 %	90.4 %	97.2 %	94.5 %	93.0 %	92.0 %	90.7 %	
Operating Leverage	-0.7 x	-13.5 x	31.5 x	11.2 x	-0.7 x	7.5 x	4.1 x	
EBITDA / Interest expenses	33.3 x	49.4 x	5.4 x	n.m.	51.3 x	61.0 x	70.9 x	
Tax rate (EBT)	14.0 %	18.1 %	35.8 %	27.7 %	30.0 %	30.0 %	30.0 %	
Dividend Payout Ratio	23.2 %	24.4 %	131.5 %	34.2 %	51.9 %	38.8 %	33.9 %	
Sales per Employee	191,744	178,720	189,658	207,649	197,802	210,989	228,571	





Consolidated balance sheet							
In EUR m	2015	2016	2017	2018	2019e	2020e	2021e
Assets							
Goodwill and other intangible assets	42.4	43.8	41.8	59.9	61.7	63.6	65.5
thereof other intangible assets	18.9	18.2	14.7	26.5	25.6	24.7	23.9
thereof Goodwill	15.2	15.5	14.5	18.0	18.0	18.0	18.0
Property, plant and equipment	2.4	2.3	2.0	2.3	7.9	7.2	6.5
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	44.7	46.0	43.8	62.2	69.7	70.8	72.0
Inventories	9.3	9.2	9.1	10.6	10.2	10.9	11.8
Accounts receivable	15.4	12.6	12.8	13.7	14.5	15.5	16.8
Liquid assets	9.2	10.9	10.3	9.7	11.8	8.6	8.2
Other short-term assets	3.8	4.2	4.7	3.7	5.8	5.8	5.8
Current assets	37.7	36.9	36.9	37.6	42.3	40.8	42.5
Total Assets	82.5	82.9	80.7	99.8	112.0	111.6	114.5
Liabilities and shareholders' equity							
Subscribed capital	7.0	7.0	7.7	9.1	9.1	9.1	9.1
Capital reserve	12.3	12.3	19.2	31.1	31.1	31.1	31.1
Retained earnings	23.1	28.4	25.4	28.0	30.7	34.7	40.0
Other equity components	0.0	0.0	0.0	0.0	-3.3	-6.1	-9.3
Shareholders' equity	42.4	47.6	52.3	68.3	67.6	68.7	71.0
Minority interest	0.0	0.0	0.0	0.1	0.1	0.1	0.1
Total equity	42.3	47.6	52.3	68.4	67.7	68.9	71.1
Provisions	4.1	4.7	2.9	3.7	5.4	5.4	5.4
thereof provisions for pensions and similar obligations	1.9	2.2	2.2	2.1	2.5	2.5	2.5
Financial liabilities (total)	21.2	16.9	12.6	12.8	21.7	19.7	19.7
thereof short-term financial liabilities	5.5	10.3	8.4	10.7	10.7	10.7	10.7
Accounts payable	6.3	5.9	5.5	6.1	6.9	7.4	8.0
Other liabilities	8.5	7.8	7.4	8.8	10.2	10.2	10.2
Liabilities	40.1	35.3	28.4	31.4	44.3	42.8	43.4
Total liabilities and shareholders' equity	82.5	82.9	80.7	99.8	112.0	111.6	114.5


Financial Ratios							
	2015	2016	2017	2018	2019e	2020e	2021e
Efficiency of Capital Employment							
Operating Assets Turnover	4.0 x	4.4 x	4.3 x	4.1 x	3.5 x	3.7 x	3.8 x
Capital Employed Turnover	1.5 x	1.4 x	1.4 x	1.1 x	1.1 x	1.2 x	1.2 x
ROA	10.0 %	12.4 %	1.6 %	5.3 %	3.8 %	5.6 %	7.5 %
Return on Capital							
ROCE (NOPAT)	8.4 %	10.5 %	2.7 %	4.5 %	3.5 %	5.0 %	6.5 %
ROE	11.3 %	12.7 %	1.4 %	5.5 %	3.9 %	5.9 %	7.7 %
Adj. ROE	11.3 %	12.7 %	1.4 %	5.5 %	3.9 %	5.9 %	7.7 %
Balance sheet quality							
Net Debt	13.9	8.3	4.5	5.2	12.4	13.6	14.1
Net Financial Debt	12.0	6.1	2.3	3.1	9.9	11.1	11.6
Net Gearing	32.8 %	17.4 %	8.6 %	7.6 %	18.3 %	19.8 %	19.8 %
Net Fin. Debt / EBITDA	112.0 %	49.4 %	33.5 %	34.2 %	96.4 %	91.3 %	81.6 %
Book Value / Share	6.1	6.8	6.8	7.5	7.4	7.5	7.8
Book value per share ex intangibles	0.0	0.6	1.4	0.9	0.6	0.6	0.6





Consolidated cash flow statement							
In EUR m	2015	2016	2017	2018	2019e	2020e	2021e
Net income	4.5	5.7	0.7	3.3	2.6	4.0	5.4
Depreciation of fixed assets	0.8	0.8	0.8	0.7	1.9	1.9	1.9
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	4.5	4.3	3.7	4.2	4.5	4.5	4.5
Increase/decrease in long-term provisions	0.0	0.0	0.0	0.0	0.4	0.0	0.0
Other non-cash income and expenses	-1.3	0.3	-0.3	0.3	0.0	0.0	0.0
Cash Flow before NWC change	8.5	11.1	4.9	8.5	9.4	10.4	11.8
Increase / decrease in inventory	-0.6	0.1	0.1	-1.5	0.4	-0.7	-0.9
Increase / decrease in accounts receivable	-1.2	2.8	-0.2	-1.4	-0.8	-1.0	-1.3
Increase / decrease in accounts payable	1.7	-0.8	-0.3	1.4	0.8	0.5	0.6
Increase / decrease in other working capital positions	0.2	-3.7	-1.0	2.4	0.0	0.0	0.0
Increase / decrease in working capital (total)	0.1	-1.6	-1.3	0.9	0.4	-1.2	-1.6
Net cash provided by operating activities [1]	8.6	9.5	3.6	9.4	9.7	9.2	10.2
Investments in intangible assets	-2.8	-4.5	-4.6	-6.4	-6.4	-6.4	-6.4
Investments in property, plant and equipment	-1.7	-1.1	-1.0	-1.4	-1.2	-1.2	-1.2
Payments for acquisitions	-1.3	-0.9	-4.2	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-5.8	-6.5	-9.8	-7.7	-7.6	-7.6	-7.6
Change in financial liabilities	-1.7	-0.2	-0.3	-1.0	2.7	-2.0	0.0
Dividends paid	-1.7	-1.0	-1.4	-1.0	-1.2	-1.4	-1.5
Purchase of own shares	1.1	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	7.9	0.0	0.0	0.0	0.0
Other	-0.2	-0.2	-0.1	-0.2	-1.5	-1.5	-1.5
Net cash provided by financing activities [3]	-2.6	-1.4	6.0	-2.2	0.0	-4.9	-3.0
Change in liquid funds [1]+[2]+[3]	0.3	1.6	-0.2	-0.5	2.2	-3.2	-0.4
Effects of exchange-rate changes on cash	0.1	0.1	-0.4	-0.1	0.0	0.0	0.0
Cash and cash equivalent at end of period	9.2	10.9	10.3	9.7	11.8	8.6	8.2

Financial Ratios							
	2015	2016	2017	2018	2019e	2020e	2021e
Cash Flow							
FCF	4.2	3.9	-2.0	1.7	2.2	1.6	2.6
Free Cash Flow / Sales	5.1 %	4.9 %	-2.6 %	2.0 %	2.4 %	1.7 %	2.5 %
Free Cash Flow Potential	6.7	6.8	2.3	1.9	2.0	3.3	4.7
Free Cash Flow / Net Profit	93.8 %	68.6 %	-283.5 %	51.4 %	82.8 %	40.7 %	48.5 %
Interest Received / Avg. Cash	0.6 %	0.6 %	0.4 %	0.7 %	0.9 %	1.0 %	1.2 %
Interest Paid / Avg. Debt	1.4 %	1.3 %	8.6 %	-3.6 %	1.2 %	1.0 %	1.0 %
Management of Funds							
Investment ratio	5.4 %	7.0 %	7.1 %	9.2 %	8.4 %	7.9 %	7.3 %
Maint. Capex / Sales	4.0 %	5.2 %	5.3 %	6.9 %	6.3 %	5.9 %	5.5 %
Capex / Dep	84.1 %	110.0 %	123.9 %	156.4 %	118.2 %	118.2 %	118.2 %
Avg. Working Capital / Sales	22.6 %	21.3 %	20.5 %	20.6 %	20.0 %	19.2 %	19.0 %
Trade Debtors / Trade Creditors	244.0 %	214.0 %	232.1 %	224.8 %	210.1 %	209.5 %	210.0 %
Inventory Turnover	3.4 x	3.4 x	3.6 x	3.5 x	3.8 x	3.7 x	3.8 x
Receivables collection period (days)	68	57	59	60	59	59	59
Payables payment period (days)	72	68	63	61	64	66	65
Cash conversion cycle (Days)	103	96	100	104	90	90	90





LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.
- 3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.
- 4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6- Companies affiliated with Warburg Research regularly trade financial instruments of the analysed company or derivatives of these.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Softing	3, 5, 6	http://www.mmwarburg.com/disclaimer_disclaimer_en/DE0005178008.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.

Rating	Number of stocks	% of Universe
Buy	120	60
Hold	67	34
Sell	7	4
Rating suspended	5	3
Total	199	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	33	79
Hold	7	17
Sell	0	0
Rating suspended	2	5
Total	42	100

PRICE AND RATING HISTORY SOFTING AS OF 16.08.2019



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Franz Schall Automobiles, Car Suppliers	+40 40 309537-230 fschall@warburg-research.com
Jan Bauer Renewables	+40 40 309537-155 jbauer@warburg-research.com	Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Jonas Blum Telco, Construction	+40 40 309537-240 jblum@warburg-research.com	Patrick Schmidt Leisure, Internet	+49 40 309537-125 pschmidt@warburg-research.com
Christian Cohrs	+49 40 309537-175	Oliver Schwarz	+49 40 309537-250
Industrials & Transportation Felix Ellmann	ccohrs@warburg-research.com +49 40 309537-120	Chemicals, Agriculture Cansu Tatar	oschwarz@warburg-research.com +49 40 309537-248
Software, IT Jörg Philipp Frey	fellmann@warburg-research.com +49 40 309537-258	Cap. Goods, Engineering Marc-René Tonn	ctatar@warburg-research.com +49 40 309537-259
Retail, Consumer Goods Marius Fuhrberg	jfrey@warburg-research.com +49 40 309537-185	Automobiles, Car Suppliers Robert-Jan van der Horst	mtonn@warburg-research.com +49 40 309537-290
Financial Services	mfuhrberg@warburg-research.com	Technology	rvanderhorst@warburg-research.com
Ulrich Huwald Health Care, Pharma	+49 40 309537-255 uhuwald@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
Philipp Kaiser Real Estate	+49 40 309537-260 pkaiser@warburg-research.com		
Thilo Kleibauer Retail, Consumer Goods	+49 40 309537-257 tkleibauer@warburg-research.com		
Eggert Kuls Engineering	+49 40 309537-256 ekuls@warburg-research.com		
INSTITUTIONAL EQUI			
Marc Niemann	+49 40 3282-2660	Matthias Fritsch	+49 40 3282-2696
Head of Equity Sales, Germany	mniemann@mmwarburg.com	United Kingdom	mfritsch@mmwarburg.com
Klaus Schilling	+49 40 3282-2664	Michael Kriszun	+49 40 3282-2695
Head of Equity Sales, Germany Tim Beckmann	kschilling@mmwarburg.com +49 40 3282-2665	United Kingdom	mkriszun@mmwarburg.com
United Kingdom	tbeckmann@mmwarburg.com		
Lyubka Bogdanova	+49 69 5050-7411		
Ireland, Poland, Australia	lbogdanova@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415	Julia Fesenberg	+49 69 5050-7417
Scandinavia, Austria	jbuchmueller@mmwarburg.com +49 40 3282-2669	Roadshow/Marketing	jfesenberg@mmwarburg.com +49 40 3282-2694
Alexander Eschweiler Germany	aeschweiler@mmwarburg.com	Juliane Niemann Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING			
Oliver Merckel	+49 40 3282-2634	Bastian Quast	+49 40 3282-2701
Head of Sales Trading	omerckel@mmwarburg.com	Sales Trading	bquast@mmwarburg.com
Elyaz Dust Sales Trading	+49 40 3282-2702 edust@mmwarburg.com	Jörg Treptow Sales Trading	+49 40 3282-2658 jtreptow@mmwarburg.com
Michael Ilgenstein Sales Trading	+49 40 3282-2700 milgenstein@mmwarburg.com	Jan Walter Sales Trading	+49 40 3282-2662 jwalter@mmwarburg.com
MACRO RESEARCH			,
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be fe			-,
Warburg Research	research.mmwarburg.com/en/index.html	Thomson Reuters	www.thomsonreuters.com
Bloomberg	MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta	ct:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com